AT13148

AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC50s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.

Product Specifications

CAS Number

[1056901-62-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Akt; PKA; Ribosomal S6 Kinase (RSK) ; ROCK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/at13148.html

Purity

99.20

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

ClC1=CC=C([C@](C2=CC=C(C3=CNN=C3)C=C2)(O)CN)C=C1

Molecular Formula

C17H16ClN3O

Molecular Weight

313.78

Precautions

H302, H315, H319, H335

References & Citations

[1]Yap TA, et al. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Clin Cancer Res. 2012 Jul 15;18 (14) :3912-23.|[2]Xi Y, et al. AT13148, a first-in-class multi-AGC kinase inhibitor, potently inhibits gastric cancer cells both in vitro and in vivo. Biochem Biophys Res Commun. 2016 Sep 9;478 (1) :330-6